Indika Leelasena

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer et al. · The Lancet Infectious Diseases · 2022 · 78 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With <i>Plasmodium falciparum</i>

Bridget E. Barber, Azrin N. Abd‐Rahman, Rebecca Webster et al. · Clinical Infectious Diseases · 2023 · 18 citations · Full text

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

Chijioke Bennett, Wayne Woo, Mark Bloch et al. · The Lancet Infectious Diseases · 2024 · 16 citations · Full text

Safety, Tolerability, and Pharmacokinetics of IMU‐935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double‐Blind, Placebo‐Controlled, First‐in‐Human Phase 1 Study

Thomas M. Polasek, Indika Leelasena, Irina Betscheider et al. · Clinical Pharmacology in Drug Development · 2023 · 14 citations · Full text

First‐in‐human Phase 1, Healthy Subjects, Immunodeficiencies +22

Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial

Ben Baker, Imogen M. Bermingham, Indika Leelasena et al. · Vaccines · 2023 · 14 citations · Full text